AU726311B2 - Triaryl substituted imidazoles and methods of use - Google Patents

Triaryl substituted imidazoles and methods of use Download PDF

Info

Publication number
AU726311B2
AU726311B2 AU54414/98A AU5441498A AU726311B2 AU 726311 B2 AU726311 B2 AU 726311B2 AU 54414/98 A AU54414/98 A AU 54414/98A AU 5441498 A AU5441498 A AU 5441498A AU 726311 B2 AU726311 B2 AU 726311B2
Authority
AU
Australia
Prior art keywords
pyridyl
imidazole
fluorophenyl
alkyl
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54414/98A
Other languages
English (en)
Other versions
AU5441498A (en
Inventor
Linda L. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700559.9A external-priority patent/GB9700559D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5441498A publication Critical patent/AU5441498A/en
Application granted granted Critical
Publication of AU726311B2 publication Critical patent/AU726311B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU54414/98A 1996-11-20 1997-11-17 Triaryl substituted imidazoles and methods of use Ceased AU726311B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3146896P 1996-11-20 1996-11-20
US60/031468 1996-11-20
GBGB9700559.9A GB9700559D0 (en) 1997-01-13 1997-01-13 Triaryl substituted imidazoles and methods of use
GB9700559 1997-01-13
PCT/US1997/020955 WO1998022108A1 (en) 1996-11-20 1997-11-17 Triaryl substituted imidazoles and methods of use

Publications (2)

Publication Number Publication Date
AU5441498A AU5441498A (en) 1998-06-10
AU726311B2 true AU726311B2 (en) 2000-11-02

Family

ID=26310784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54414/98A Ceased AU726311B2 (en) 1996-11-20 1997-11-17 Triaryl substituted imidazoles and methods of use

Country Status (5)

Country Link
EP (1) EP0959885A4 (de)
JP (1) JP2001504489A (de)
AU (1) AU726311B2 (de)
CA (1) CA2271941A1 (de)
WO (1) WO1998022108A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
PT1741446E (pt) 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2004513935A (ja) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003024447A1 (en) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2004058727A1 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
PL1931350T5 (pl) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
EP3065736B1 (de) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
WO2015119579A1 (en) * 2014-02-07 2015-08-13 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016141381A2 (en) * 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
US11958828B1 (en) 2023-11-07 2024-04-16 King Faisal University 4,5-bis(4-bromophenyl)-1-hexyl-2-(3-pyridyl)-1H-imidazole as an antimicrobial compound
US12180169B1 (en) 2023-12-28 2024-12-31 King Faisal University 4-[4,4-bis(4-bromophenyl)-5-oxo-2-thioxoimidazolidin-1-yl]butanoic acid as an antimicrobial compound
US11993575B1 (en) 2023-12-29 2024-05-28 King Faisal University Ethyl [4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]acetate as an antimicrobial compound
US12180168B1 (en) 2024-01-02 2024-12-31 King Faisal University 3-[4,4-bis(4-nitrophenyl)-2,5-dioxoimidazolidin-1-yl]propanoic acid as an antimicrobial compound
US12180167B1 (en) 2024-01-02 2024-12-31 King Faisal University 6-[4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]hexanoic acid as an antimicrobial compound
US11970462B1 (en) 2024-01-03 2024-04-30 King Faisal University Ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate as an antimicrobial compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772441A (en) * 1970-11-16 1973-11-13 Pfizer Anti-inflammatory imidazoles
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5686455A (en) * 1992-01-13 1997-11-11 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772441A (en) * 1970-11-16 1973-11-13 Pfizer Anti-inflammatory imidazoles
US5686455A (en) * 1992-01-13 1997-11-11 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
CA2271941A1 (en) 1998-05-28
WO1998022108A1 (en) 1998-05-28
EP0959885A1 (de) 1999-12-01
JP2001504489A (ja) 2001-04-03
AU5441498A (en) 1998-06-10
EP0959885A4 (de) 2002-07-17

Similar Documents

Publication Publication Date Title
AU726311B2 (en) Triaryl substituted imidazoles and methods of use
AU730295B2 (en) Triaryl substituted imidazoles as glucagon antagonists
US5880139A (en) Triaryl substituted imidazoles as glucagon antagonists
AU728760B2 (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
KR102698413B1 (ko) 헤테로방향족 거대환식 에터 화학치료제
JP7815341B2 (ja) ヘテロ芳香族大環状エーテル化学療法剤
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
JP5171918B2 (ja) キナーゼ阻害剤として有用なアミノインダゾール誘導体を合成するための中間体化合物
EP1789419B1 (de) Gyraseinhibitoren und deren verwendungen
CA3179181A1 (en) Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
JP3110467B2 (ja) キノキサリンジオン類
JPH10503211A (ja) 炎症の処置のための１，２−置換イミダゾリル化合物
IL169720A (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
CA2432870A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
CA2513631A1 (fr) Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR20170012432A (ko) 피라졸 화합물 및 ｔ-형 칼슘 채널 차단제로서의 이의 용도
US5955480A (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JP2020504706A (ja) 置換窒素含有化合物
CN120129677A (zh) 化合物及其用于治疗血红素病变的用途
EA049608B1 (ru) Химиотерапевтические агенты на основе гетероароматического макроциклического эфира
FR2844267A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
WO2005060971A1 (en) Treatment of reflux-related diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired